靶向结核耐药机制的抗结核药物增效剂的研究进展  

Advancements in anti-tuberculosis drug potentiators:targeting mechanisms of tuberculosis resistance

作　　者：杨建慧 王潇[2] 张金波[1] 刘忆霜[2] Jianhui Yang;Xiao Wang;Jinbo Zhang;Yishuang Liu(School of Basic Medicine,Jiamusi University,Jiamusi 154007,Heilongjiang,China;National Key Laboratory for Screening New Microbial Drugs,Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China)

机构地区：[1]佳木斯大学基础医学院,黑龙江佳木斯154007 [2]中国医学科学院北京协和医学院医药生物技术研究所,国家新药(微生物)筛选实验室,北京100050

出　　处：《Journal of Chinese Pharmaceutical Sciences》2024年第2期89-97,共9页中国药学（英文版）

基　　金：CAMS Innovation Fund for Medical Sciences(Grant No.CIFMS,2021-I2M-1-028);the National Natural Science Foundation of China(Grant No.81903678).

摘　　要：结核病(Tuberculosis,TB)是一个全球性的健康问题,由于耐多药结核病(multidrug-resistant tuberculosis,MDR-TB)菌株的出现,抗结核药物出现防治困难。针对耐药机制开发抗结核药物的增效剂可以减少耐药性的出现和缩短治疗时间。本文从靶向细胞壁、外排泵和β-内酰胺酶的增效剂与抗结核药物的联合应用进行综述,为后续开发活性更好、毒性更小的新型增效剂提供参考。Tuberculosis(TB)constitutes a formidable global health challenge,exacerbated by the rise of multidrug-resistant TB(MDR-TB)strains.The effectiveness of anti-TB drugs has been hindered by this emergence of resistance.To address this,the development of synergistic compounds,informed by drug resistance mechanisms,holds promise for mitigating resistance emergence and shortening treatment durations.This review focuses on the amalgamation of anti-TB drugs with potentiators targeting the cell wall,efflux pump,andβ-lactamase.Our aim is to offer insights that guide the future development of novel potentiators with enhanced efficacy and reduced toxicity.

关 键 词：结核病 耐药菌株 抗结核药物增效剂 

分 类 号：R965[医药卫生—药理学]